This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 103/9/983    most recent CIRCRESAHA.108.178970v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Das, S. Articles by Steenbergen, C. Search for Related Content PubMed PubMed Citation Articles by Das, S. Articles by Steenbergen, C. Related Collections Biochemistry and metabolism Cell signalling/signal transduction Energy metabolism Ischemic biology - basic studies Related Article

(Circulation Research. 2008;103:983.)
© 2008 American Heart Association, Inc.

Cellular Biology

Glycogen Synthase Kinase 3 Inhibition Slows Mitochondrial Adenine Nucleotide Transport and Regulates Voltage-Dependent Anion Channel Phosphorylation

Samarjit Das, Renee Wong, Nishadi Rajapakse, Elizabeth Murphy, Charles Steenbergen

From the Department of Pathology (S.D., C.S.), Johns Hopkins University, Baltimore, Md; Cardiac Physiology Section (R.W., E.M.), Vascular Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Md; and Laboratory of Signal Transduction (N.R.), National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC.

Correspondence to Charles Steenbergen, MD, PhD, Department of Pathology, Johns Hopkins University, 632N Ross Research Building, 720 Rutland St, Baltimore, MD 21205. E-mail csteenb1{at}jhmi.edu

Inhibition of glycogen synthase kinase (GSK)-3 reduces ischemia/reperfusion injury by mechanisms that involve the mitochondria. The goal of this study was to explore possible molecular targets and mechanistic basis of this cardioprotective effect. In perfused rat hearts, treatment with GSK inhibitors before ischemia significantly improved recovery of function. To assess the effect of GSK inhibitors on mitochondrial function under ischemic conditions, mitochondria were isolated from rat hearts perfused with GSK inhibitors and were treated with uncoupler or cyanide or were made anoxic. GSK inhibition slowed ATP consumption under these conditions, which could be attributable to inhibition of ATP entry into the mitochondria through the voltage-dependent anion channel (VDAC) and/or adenine nucleotide transporter (ANT) or to inhibition of the F₁F₀-ATPase. To determine the site of the inhibitory effect on ATP consumption, we measured the conversion of ADP to AMP by adenylate kinase located in the intermembrane space. This assay requires adenine nucleotide transport across the outer but not the inner mitochondrial membrane, and we found that GSK inhibitors slow AMP production similar to their effect on ATP consumption. This suggests that GSK inhibitors are acting on outer mitochondrial membrane transport. In sonicated mitochondria, GSK inhibition had no effect on ATP consumption or AMP production. In intact mitochondria, cyclosporin A had no effect, indicating that ATP consumption is not caused by opening of the mitochondrial permeability transition pore. Because GSK is a kinase, we assessed whether protein phosphorylation might be involved. Therefore, we performed Western blot and 1D/2D gel phosphorylation site analysis using phos-tag staining to indicate proteins that had decreased phosphorylation in hearts treated with GSK inhibitors. Liquid chromatographic–mass spectrometric analysis revealed 1 of these proteins to be VDAC2. Taken together, we found that GSK-mediated signaling modulates transport through the outer membrane of the mitochondria. Both proteomics and adenine nucleotide transport data suggest that GSK regulates VDAC and that VDAC may be an important regulatory site in ischemia/reperfusion injury.

Key Words: mitochondria • GSK-3 • VDAC • adenine nucleotide transport

Related Article:

Overcoming an Energy Crisis?: An Adaptive Role of Glycogen Synthase Kinase-3 Inhibition in Ischemia/Reperfusion

Peiyong Zhai and Junichi Sadoshima
Circ. Res. 2008 103: 910-913. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				D. B. Zorov, M. Juhaszova, Y. Yaniv, H. B. Nuss, S. Wang, and S. J. Sollott Regulation and pharmacology of the mitochondrial permeability transition pore Cardiovasc Res, July 15, 2009; 83(2): 213 - 225. [Abstract] [Full Text] [PDF]

				M. Juhaszova, D. B. Zorov, Y. Yaniv, H. B. Nuss, S. Wang, and S. J. Sollott Role of Glycogen Synthase Kinase-3{beta} in Cardioprotection Circ. Res., June 5, 2009; 104(11): 1240 - 1252. [Abstract] [Full Text] [PDF]

				S. Miyamoto, M. Rubio, and M. A. Sussman Nuclear and mitochondrial signalling Akts in cardiomyocytes Cardiovasc Res, May 1, 2009; 82(2): 272 - 285. [Abstract] [Full Text] [PDF]

				P. Zhai and J. Sadoshima Overcoming an Energy Crisis?: An Adaptive Role of Glycogen Synthase Kinase-3 Inhibition in Ischemia/Reperfusion Circ. Res., October 24, 2008; 103(9): 910 - 913. [Full Text] [PDF]